Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

A nanobody (Nb) is a registered trademark of Ablynx, referring to the single antigen‐binding
domain of heavy chain‐only antibodies (HCAbs) that are circulating in Camelidae. Nbs are …

Chemical biology strategies for directly perturbing protein homeostasis including the
degradation tag (dTAG) system provide temporal advantages over genetic approaches and …

Over the past 3 years, the first bivalent protein degraders intentionally designed for targeted
protein degradation (TPD) have advanced to clinical trials, with an initial focus on …

Targeted protein degradation (TPD), the ability to control a proteins fate by triggering its
degradation in a highly selective and effective manner, has created tremendous excitement …

Over the last two decades, nanobodies or single-domain antibodies have found their way in
research, diagnostics, and therapy. These antigen-binding fragments, derived from Camelid …

Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms
and involve many different amino-acids. Therefore, molecules able to interfere with mutant …

Activating mutants of RAS are commonly found in human cancers, but to date selective
targeting of RAS in the clinic has been limited to KRAS (G12C) through covalent inhibitors …

Reagents that bind tightly and specifically to biomolecules of interest remain essential in the
exploration of biology and in their ultimate application to medicine. Besides ligands for …

Inducing post-translational protein knockdown is an important approach to probe biology
and validate drug targets. An efficient strategy to achieve this involves expression of a …